Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Adlai Nortye Ltd. - American Depositary Shares Market Cap
From what 0 stock analysts predict, the share price for Adlai Nortye Ltd. - American Depositary Shares (ANL) might increase by 378.72% in the next year. This is based on a 12-month average estimation for ANL. Price targets go from $9 to $9. The majority of stock analysts believe ANL is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
ANL is a stock in Healthcare which has been forecasted to be worth $9 as an average. On the higher end, the forecast price is $9 USD by Joseph Pantginis from HC Wainwright & Co. and on the lower end ANL is forecasted to be $9 by Joseph Pantginis from HC Wainwright & Co..
These are the latest 20 analyst ratings of ANL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $9 | Initiates | Sep 4, 2024 |
| Louise Chen Cantor Fitzgerald | Overweight | Reiterates | Jun 20, 2024 | |
| Louise Chen Cantor Fitzgerald | Overweight | $30 | Initiates | Oct 24, 2023 |
When did it IPO
N/A
Staff Count
127
Country
Cayman Islands
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Yang Lu
Market Cap
$69.4M
In 2023, ANL generated $5.0M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ANL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Sep 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Adlai Nortye Ltd. (ANL) is now considered technically oversold, indicating a potential exhaustion of heavy selling pressure on the stock.
Why It Matters - ANL being technically oversold signals potential price recovery, attracting buyers and possibly leading to a rebound, which could enhance investor returns.
Wed, 22 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Adlai Nortye Ltd. (NASDAQ: ANL) has initiated a Phase II clinical trial, ARTEMIS, for its EP4 antagonist, palupiprant, aimed at treating rectal cancer alongside chemoradiotherapy.
Why It Matters - The initiation of the Phase II trial for Adlai Nortye's cancer therapy could signal advancements in cancer treatment, impacting stock performance and investor sentiment in biotech.
Thu, 23 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Adlai Nortye Ltd. (NASDAQ: ANL) will present preliminary data on its cancer therapy AN0025 at the ASCO Annual Meeting from May 31 to June 4, 2024, focusing on esophageal cancer treatment.
Why It Matters - Preliminary data on AN0025 could indicate a significant breakthrough in cancer treatment, potentially boosting Adlai Nortye's stock value and attracting investor interest.
Wed, 15 May 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Adlai Nortye Ltd. (ANL) and Boston Scientific (BSX) have shown performance metrics relative to their sector in 2023. Further details on specific performance were not provided.
Why It Matters - Performance comparisons highlight relative strength or weakness, influencing investment decisions and sentiment towards Adlai Nortye and Boston Scientific within their sectors.
Thu, 25 Apr 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Adlai Nortye Ltd. (ANL) and Elevance Health (ELV) have shown performance metrics in comparison to their respective sectors in 2023. Further details on performance were not provided.
Why It Matters - The performance comparison of Adlai Nortye and Elevance Health against their sector indicates potential investment opportunities or risks, influencing portfolio decisions.
Fri, 29 Mar 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Adlai Nortye Ltd. appointed Dr. Archie Tse as Head of Research & Development, effective March 29, 2024, reporting to CEO Carsten Lu. The company focuses on innovative cancer therapies.
Why It Matters - The appointment of Dr. Archie Tse as Head of R&D may signal a strategic shift or enhancement in Adlai Nortye's cancer therapy development, potentially influencing future product pipelines and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
